JP6997919B2 - がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 - Google Patents

がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 Download PDF

Info

Publication number
JP6997919B2
JP6997919B2 JP2018545874A JP2018545874A JP6997919B2 JP 6997919 B2 JP6997919 B2 JP 6997919B2 JP 2018545874 A JP2018545874 A JP 2018545874A JP 2018545874 A JP2018545874 A JP 2018545874A JP 6997919 B2 JP6997919 B2 JP 6997919B2
Authority
JP
Japan
Prior art keywords
cancer
grp78
cells
administered
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507166A5 (enExample
JP2019507166A (ja
Inventor
スザンヌ ベイクウェル，
ジョティ セスラマン，
Original Assignee
ボールド セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボールド セラピューティクス インコーポレイテッド filed Critical ボールド セラピューティクス インコーポレイテッド
Publication of JP2019507166A publication Critical patent/JP2019507166A/ja
Publication of JP2019507166A5 publication Critical patent/JP2019507166A5/ja
Priority to JP2021125151A priority Critical patent/JP7513574B2/ja
Application granted granted Critical
Publication of JP6997919B2 publication Critical patent/JP6997919B2/ja
Priority to JP2022204252A priority patent/JP2023024618A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2018545874A 2016-03-01 2017-03-01 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 Active JP6997919B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021125151A JP7513574B2 (ja) 2016-03-01 2021-07-30 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
JP2022204252A JP2023024618A (ja) 2016-03-01 2022-12-21 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301786P 2016-03-01 2016-03-01
US62/301,786 2016-03-01
PCT/US2017/020209 WO2017151775A1 (en) 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021125151A Division JP7513574B2 (ja) 2016-03-01 2021-07-30 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用

Publications (3)

Publication Number Publication Date
JP2019507166A JP2019507166A (ja) 2019-03-14
JP2019507166A5 JP2019507166A5 (enExample) 2020-04-09
JP6997919B2 true JP6997919B2 (ja) 2022-01-18

Family

ID=59744351

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018545874A Active JP6997919B2 (ja) 2016-03-01 2017-03-01 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
JP2021125151A Active JP7513574B2 (ja) 2016-03-01 2021-07-30 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
JP2022204252A Pending JP2023024618A (ja) 2016-03-01 2022-12-21 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021125151A Active JP7513574B2 (ja) 2016-03-01 2021-07-30 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
JP2022204252A Pending JP2023024618A (ja) 2016-03-01 2022-12-21 がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用

Country Status (8)

Country Link
US (3) US10821095B2 (enExample)
EP (1) EP3423055A4 (enExample)
JP (3) JP6997919B2 (enExample)
KR (2) KR20220075450A (enExample)
CN (1) CN109195600A (enExample)
AU (1) AU2017227705A1 (enExample)
IL (2) IL299223A (enExample)
WO (2) WO2017151775A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220075450A (ko) * 2016-03-01 2022-06-08 인터자인 테크놀로지스, 인코포레이티드 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
US11730750B2 (en) 2020-02-17 2023-08-22 University Of Kentucky Research Foundation Drugs for GRP78 cell surface translocation and Par-4 secretion
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
US20250235465A1 (en) * 2021-10-28 2025-07-24 Bold Therapeutics Inc. Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] to ameliorate proteasome inhibitor resistance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531065A (ja) 2010-07-18 2013-08-01 ニッキ ファーマ インク． ルテニウム錯体を用いる併用療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2152084E (pt) 2007-06-11 2014-01-23 Niiki Pharma Inc Método de fabrico de um complexo de ruténio
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
WO2016029073A2 (en) 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
KR20220075450A (ko) * 2016-03-01 2022-06-08 인터자인 테크놀로지스, 인코포레이티드 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531065A (ja) 2010-07-18 2013-08-01 ニッキ ファーマ インク． ルテニウム錯体を用いる併用療法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BMC Pharmacology & Toxicology，2012, Vol.13, Supplement 1，Article No.A82
Chemical Science，2014, Vol.5, No.8，pp.2925-2932
Molecular Cancer Therapeutics，2016, Vol.15, No.5，pp.1043-1052
Nature Reviews Cancer，2014, Vol.14, No.4，pp.263-276

Also Published As

Publication number Publication date
AU2017227705A9 (en) 2018-12-20
WO2017151775A9 (en) 2018-09-13
KR102413412B1 (ko) 2022-06-28
CN109195600A (zh) 2019-01-11
IL299223A (en) 2023-02-01
KR20220075450A (ko) 2022-06-08
JP2021167360A (ja) 2021-10-21
EP3423055A4 (en) 2019-10-16
US20210085647A1 (en) 2021-03-25
US10821095B2 (en) 2020-11-03
JP2019507166A (ja) 2019-03-14
IL261384A (en) 2018-10-31
EP3423055A1 (en) 2019-01-09
IL261384B2 (en) 2023-05-01
IL261384B1 (en) 2023-01-01
WO2017151762A1 (en) 2017-09-08
AU2017227705A1 (en) 2018-10-18
US20240091196A1 (en) 2024-03-21
US20190038601A1 (en) 2019-02-07
KR20180130509A (ko) 2018-12-07
JP2023024618A (ja) 2023-02-16
US11633380B2 (en) 2023-04-25
JP7513574B2 (ja) 2024-07-09
WO2017151775A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
JP7513574B2 (ja) がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
Osada et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations
Cao et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells
Matsuo et al. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis
Mabuchi et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
Ji et al. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer
Chan et al. CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma
Fu et al. Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma
Zhuang et al. Solasodine inhibits human colorectal cancer cells through suppression of the AKT/glycogen synthase kinase‐3β/β‐catenin pathway
Afolabi et al. Synergistic tumor cytolysis by NK cells in combination with a pan-HDAC inhibitor, panobinostat
Lee et al. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer
Rosemblit et al. Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies
JP2018513123A (ja) Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
Shin et al. Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization
CN114126652A (zh) 抗肿瘤剂和配合剂
US10675289B2 (en) Methods of treating pancreatic cancer
Chen et al. Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn/AhR/IL-6 and pol ζ-prevented CIN in human oral squamous cell carcinoma
Chen et al. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib
CN111208283A (zh) 增效的肿瘤抑制组合物及其应用
US20250387370A1 (en) Use of trans-[tetrachlorobis(1h-indazole)ruthenate(iii)] for the treatment of cancer
Khaleel et al. CXCR4/CXCL12 blockade therapy; a new horizon in TNBC therapy
Gupta et al. Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis
Gupta et al. Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis: Translational Therapeutics
CN120585840A (zh) 一种抑制TRIM25和HIF-1α结合的化合物在制备治疗肿瘤药物中的应用
TOGETHER memo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211004

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211101

R150 Certificate of patent or registration of utility model

Ref document number: 6997919

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250